All patients > 18 years at diagnosis
n=1167 (100%) median OS 11.3 years

Primary disease only at diagnosis
n=891 (76.3%) median OS 13.6 years

Metastatic disease at diagnosis
n=276 (23.7%) median OS 6.4 years

No report of metastatic disease at last follow-up, recent/regular updates
n=205 median OS undefined

P value <0.0001
HR=2.623

Developed metastatic disease at a later time point
n=487 median OS 11.7 years

P value <0.0001
HR=2.440

Note:
Points towards higher hazard

<table>
<thead>
<tr>
<th>Metastatic disease at diagnosis* (n=276)</th>
<th>Median OS 6.4 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary disease only at diagnosis (n=891)</td>
<td>13.6 years</td>
</tr>
<tr>
<td>P value &lt;0.0001</td>
<td>Hazard Ratio 3.075</td>
</tr>
</tbody>
</table>

*This group represents an easily defined group that is most similar to published results for metastatic imatinib trials. Patients less than 18 years old at diagnosis were excluded.

Later had a recurrence* (n=487)
Median OS 11.7 years

No recurrence, regular updates (n=205)
Median OS undefined

P value <0.0001
Hazard Ratio 2.623

Both groups exclude patients diagnosed below the age of 18.

*This group presented with primary disease only and later had a recurrence.